For future access to innovative technologies/
novel therapeutic drug targets and collaboration
with early stage startup companies
Mission
Ono Venture Investment, Inc. (OVI) is the corporate venture capital arm of Ono Pharmaceutical Co.,Ltd. ,
an R&D-oriented pharmaceutical company succeeded in delivery of “First in class”
medicines to patients such as OPDIVO® (nivolumab).
Priority Areas
-
Oncology
-
Immunology
-
Neurology
-
Specialty
To fulfill our mission as a Corporate Venture Capital, OVI prioritizes to make investment in novel startups possessing products and
platforms potentially with high synergy to R&D of our parent company, Ono Pharmaceutical Co.,Ltd. .
